Skip to main content
NCBI home page
Journal of Neurology, Neurosurgery, and Psychiatry logoLink to Journal of Neurology, Neurosurgery, and Psychiatry
. 1973 Jun;36(3):354–361. doi: 10.1136/jnnp.36.3.354

Interactions of L-dopa and amantadine in patients with Parkinsonism

B Cox 1,2, G Danta 1,2,1, H Schnieden 1,2, G M Yuill 1,2
PMCID: PMC494333  PMID: 4714097

Abstract

Twenty-seven patients with Parkinson's disease participated in a double-blind crossover trial of L-dopa and amantadine. Each drug was given for six weeks, and six weeks were allowed to elapse between the two periods of treatment. Marked improvement occurred in patients given L-dopa first, whereas no clinical effect was observed in those patients treated first with amantadine. L-dopa was less beneficial to patients who had previously received amantadine, whereas amantadine became effective in patients who had previously taken L-dopa. The effect of pre-treatment with one drug on the therapeutic effectiveness of the other drug is reflected in changes of homovanillic acid levels in the cerebrospinal fluid.

Full text

PDF
354

Images in this article

355Image
on p.355

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. AGATE F. J., Jr, DOSHAY L. J., CURTIS F. K. Quantitative measurement of therapy in paralysis agitans. J Am Med Assoc. 1956 Feb 4;160(5):352–354. doi: 10.1001/jama.1956.02960400010003. [DOI] [PubMed] [Google Scholar]
  2. ANDEN N. E., ROOS B. E., WERDINIUS B. On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorometric method. Life Sci. 1963 Jul;(7):448–458. doi: 10.1016/0024-3205(63)90132-2. [DOI] [PubMed] [Google Scholar]
  3. Bleidner W. E., Harmon J. B., Hewes W. E., Lynes T. E., Hermann E. C. Absorption, distribution and excretion of amantadine hydrochloride. J Pharmacol Exp Ther. 1965 Dec;150(3):484–490. [PubMed] [Google Scholar]
  4. Calne D. B., Stern G. M., Laurence D. R., Sharkey J., Armitage P. L-dopa in postencephalitic parkinsonism. Lancet. 1969 Apr 12;1(7598):744–746. doi: 10.1016/s0140-6736(69)91751-6. [DOI] [PubMed] [Google Scholar]
  5. Calne D. B., Stern G. M., Spiers A. S., Laurence D. R. L-dopa in idiopathic parkinsonism. Lancet. 1969 Nov 8;2(7628):973–976. doi: 10.1016/s0140-6736(69)90536-4. [DOI] [PubMed] [Google Scholar]
  6. Fieschi C., Nardini M., Casacchia M., Tedone M. E., Reitano M., Robotti E. Amantadine versus L-2 dopa and amatadine plus L-dopa. Lancet. 1970 Jul 18;2(7664):154–155. doi: 10.1016/s0140-6736(70)92742-x. [DOI] [PubMed] [Google Scholar]
  7. Fletcher E. A., Redfern P. H. The effect of amantadine on the uptake of dopamine and noradrenaline by rat brain homogenates. J Pharm Pharmacol. 1970 Dec;22(12):957–959. doi: 10.1111/j.2042-7158.1970.tb08486.x. [DOI] [PubMed] [Google Scholar]
  8. Godwin-Austen R. B., Frears C. C., Bergmann S., Parkes J. D., Knill-Jones R. P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Aug 22;2(7669):383–385. doi: 10.1016/s0140-6736(70)90002-4. [DOI] [PubMed] [Google Scholar]
  9. Godwin-Austen R. B., Tomlinson E. B., Frears C. C., Kok H. W. Effects of L-dopa in Parkinson's disease. Lancet. 1969 Jul 26;2(7613):165–168. doi: 10.1016/s0140-6736(69)91417-2. [DOI] [PubMed] [Google Scholar]
  10. Gomirato G., Perfetti C. L'associazione terapeutica L-dopa amantadina. Primi risultati in un gruppo di to Parkinsoniani. Riv Neurobiol. 1970 Jul-Sep;16(3):247–254. [PubMed] [Google Scholar]
  11. Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Amantadine in parkinsonism. Lancet. 1970 May 30;1(7657):1127–1129. doi: 10.1016/s0140-6736(70)91210-9. [DOI] [PubMed] [Google Scholar]
  12. Hunter K. R., Stern G. M., Laurence D. R., Armitage P. Combined treatment of parkinsonism with L-dopa and amantadine. Lancet. 1970 Sep 12;2(7672):566–566. doi: 10.1016/s0140-6736(70)91365-6. [DOI] [PubMed] [Google Scholar]
  13. Mawdsley C. Treatment of Parkinsonism with Laevo-dopa. Br Med J. 1970 Feb 7;1(5692):331–337. doi: 10.1136/bmj.1.5692.331. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Parkes J. D., Calver D. M., Zilkha K. J., Knill-Jones R. P. Controlled trial of amantadine hydrochloride in Parkinson's disease. Lancet. 1970 Feb 7;1(7641):259–262. doi: 10.1016/s0140-6736(70)90634-3. [DOI] [PubMed] [Google Scholar]
  15. Schnieden H. An apparatus for measuring passive resistance to movement of the forearm in man. Br J Pharmacol. 1969 Oct;37(2):542P–543P. [PMC free article] [PubMed] [Google Scholar]
  16. Stromberg U., Svensson T. H., Waldeck B. On the mode of action of amantadine. J Pharm Pharmacol. 1970 Dec;22(12):959–962. doi: 10.1111/j.2042-7158.1970.tb08487.x. [DOI] [PubMed] [Google Scholar]
  17. Webster D. D. Critical analysis of the disability in Parkinson's disease. Mod Treat. 1968 Mar;5(2):257–282. [PubMed] [Google Scholar]
  18. Weeth J. B., Shealy C. N., Mercier D. A. L-dopa and amantadine in the therapy of parkinsonism. Wis Med J. 1969 Nov;68(11):325–328. [PubMed] [Google Scholar]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group

RESOURCES